Journal article
Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T)
Future oncology (London, England), Vol.12(6), pp.751-762
01/01/2016
DOI: 10.2217/fon.16.13
PMID: 26837440
Abstract
Targeted therapy and immunotherapy have revolutionized the treatment of advanced melanoma. Despite recent advances, lack of long-term efficacy from targeted therapy and serious immune-related toxicity are major concerns. There is unmet need for 'durable' and 'safe' treatment options for advanced melanoma. Cancer vaccine therapy in melanoma has been investigated for many years with modest clinical efficacy. More recently, dendritic cell-based vaccine products have become available for clinical use and have been the focus of investigation. CLBS20 (NBS20/eltrapuldencel-T) is a novel dendritic cell-based vaccine product that has shown promising results in early phase trials in advanced melanoma. This cancer vaccine approach could play an important role in providing a sustainable survival benefit, targeting cancer cells themselves and avoiding off-target immune-related toxicity.
Details
- Title: Subtitle
- Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T)
- Creators
- Asad Javed - Thomas Jefferson UniversityShingo Sato - Thomas Jefferson UniversityTakami Sato - Thomas Jefferson University
- Resource Type
- Journal article
- Publication Details
- Future oncology (London, England), Vol.12(6), pp.751-762
- Publisher
- Future Medicine Ltd
- DOI
- 10.2217/fon.16.13
- PMID
- 26837440
- ISSN
- 1479-6694
- eISSN
- 1744-8301
- Number of pages
- 12
- Language
- English
- Date published
- 01/01/2016
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359832702771
Metrics
14 Record Views